Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc. has demonstrated a robust efficacy profile for its therapy TARA-002, with a notable 100% durability and an 80% salvage rate upon re-induction observed at the 6-month mark, surpassing earlier results at 3 months. The positive outcomes from Ph2 trials for the intravenous choline chloride therapy indicate significant improvements in liver health, with radiographic assessments revealing enhanced management of liver steatosis compared to placebo. These developments, alongside TARA-002's strong safety profile and potential competitive advantages in the non-muscle invasive bladder cancer (NMIBC) landscape, position Protara Therapeutics favorably for future adoption and market success.

Bears say

Protara Therapeutics Inc reported a substantial net loss of $12.7 million, translating to ($0.48) per share in the fourth quarter of 2024, highlighting ongoing financial challenges. Despite promising early results for its TARA-002 program in non-muscle invasive bladder cancer (NMIBC), the company's stock is trading at a significant discount compared to peers, which may indicate investor skepticism about its long-term viability and market positioning. Furthermore, the competitive landscape for NMIBC creates additional pressure, particularly as current treatments like ANKTIVA face supply constraints, potentially hindering Protara's growth.

TARA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 8 analysts, TARA has a Buy consensus rating as of Jun 20, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.